Steffen joined ADVANZ PHARMA as CEO in April 2022 and has broad general management experience in international life science businesses. He is a medical doctor by training, has previously held senior roles with STADA, Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain. His industry experience covers Biotech, Pharma, MedTech, Biosimilars, Generics, and OTC. He lead businesses in context of large European-based multinational Pharmaco, US-based Biotech, and Private Equity portfolio companies and likes to work with strong teams to drive business growth, transformation, and M&A

Andreas Stickler joined ADVANZ PHARMA from Merck Healthcare, part of Merck KGaA, where he was Chief Financial Officer and also served as Global Head of M&A and Business Development for many years. Before that, he held several finance roles at Hoechst/Aventis and Degussa/Evonik in Treasury, Capital Markets and Risk Management and brings a wealth of Finance, Healthcare and M&A expertise to the team.

Susanna brings over 15 years of leadership experience in the pharmaceutical industry, specialising in leading buy and build initiatives, transformational turnarounds, organic pipeline development, and devising and implementing strategic plans for geographic expansion. Susanna is responsible for M&A, BD&L and Data and Market Intelligence at ADVANZ and will drive the development and execution of the company’s growth plans.

Prior to joining ADVANZ, she played a pivotal role in the establishment and growth of PE-backed Theramex, where she was part of the core management team who carved-out more than 20 assets across multiple geographies to create a stand-alone specialty pharmaceutical company.

Chris joined ADVANZ PHARMA in January 2022 and brings over 25 years of pharmaceutical industry experience in R&D, project management and business/corporate development. He previously led Global M&A activities at both Neuraxpharm and Sandoz in addition to holding senior corporate development roles at Sanofi and GSK and has executed transactions across multiple jurisdictions and therapeutic areas. Having originally trained as a scientist, Chris has also spent time in financial advisory exclusively focused on the biopharma sector.

Javier has over 30 years’ experience within the pharmaceutical industry spending time in both ‘big’ pharma and within the biotech space. He was most recently the Region VP for Iberia, France, and ROW at Intercept. Previously he worked at Human Genome Sciences, Vertex, and Biogen. Javier has deep and diverse experience across multiple therapeutic areas in both innovative and mature products. Javier holds bachelor’s degree in law and has complemented his education with an Executive MBA at the Instituto de Empresa Business School.

Simon has worked in the Pharma industry for over 24 years initially joining Pfizer in the UK. Simon has had over 20 years’ experience within the ADVANZ family of companies and has focused the majority of his career Internationally being responsible for both direct and indirect business across Europe, North America, MENA, Latin America and Asia whilst living and working in the USA, UK and Jersey. Simon holds an International Business degree and has over the years built up a huge network of International pharma partners across the world many of which continue to successfully distribute and promote the wide portfolio of ADVANZ products.

Karl has more than 30 years of experience in manufacturing, packaging, supply chain and distribution, and 20 years in senior management and leadership positions including his role as Operations Director for Teva. As Chief Operations Officer for ADVANZ PHARMA, Karl leads all operations functions globally, including scientific affairs (medical, regulatory and quality), supply (supply chain and supplier alliance management), new product introductions and technical operations.

Dr Nick Warwick has over 30 years of experience both in the pharmaceutical industry and as a medical doctor. Nick trained as a medical Doctor at Charing Cross Hospital Medical School in London, now part of the Imperial College group, and spent 10 years in clinical medicine rotating through disciplines including emergency medicine, rheumatology and rehabilitation, dermatology, ear nose and throat surgery, obstetrics and gynaecology, and primary care, before joining the Pharmaceutical Industry in 1997 as Medical Adviser for Abbott. In the following 24 years, Nick held senior country level, regional and global leadership roles within Medical Affairs and Clinical Development (Abbott and Abbvie) and was Chief Medical Officer for Sandoz (2014-2019). Nick joined ADVANZ PHARMA as Chief Medical Officer in June 2020. He is responsible for setting the medical vision and strategic direction for the Medical Office (comprising medical affairs, patient safety, clinical development and medical compliance functions), ensuring that ADVANZ PHARMA has the right resources, skills and capabilities to meet its growing business needs and that the voice of the patient and healthcare professional is fully represented in all company decisions.

Nick holds a Bachelor of Medicine, Bachelor of Surgery from Charing Cross Hospital Medical School, London (MBBS, 1986), and a Diploma from the Royal College of Obstetrics and Gynaecologists, London (DRCOG, 1992) and a Diploma of Pharmaceutical Medicine from the University of Wales, Cardiff (DPM, 1998). He has been a Fellow of the Faculty of Pharmaceutical Physicians (FFPM) since 2010.

Anke joined ADVANZ PHARMA in October 2021. She brings over 15 years’ experience from strategic and operational management positions in the pharmaceutical and consulting industry and will be essential in leading the company’s transformation journey as it continues its expansion focusing on commercialising complex medicines in Europe to even better serve our patients and customers.

A pharmacist by training, she holds a PhD in molecular biology. Prior to joining ADVANZ PHARMA, Anke worked at McKinsey, HgCapital and most recently, held various global roles across Strategy, Launch and Portfolio Management as well building and driving the local German ehealth Strategy at Sandoz.

Fiona Huzarski has worked for over 20 years as a senior HR professional, 15 years within the Pharmaceuticals industry. As Vice President of Global HR, she is responsible for leading the Global HR function and setting the People Strategy to create an inclusive, flexible and collaborative environment where all employees can grow and develop in support of the company’s long-term goals.

Prior to joining ADVANZ PHARMA as Vice President of Global HR in August 2019, she was Global HR Director at Britannia Pharmaceuticals, part of the STADA group. Her career started in the Management Consulting sector before joining GSK’s Global Recruitment Team and working for 10 years at UCB in various Senior HR roles, supporting the Commercial, R&D and Technical Operations functions in both UK & Ireland and across Europe. She is a Fellow of the Chartered Institute of Personnel & Development (CIPD) and holds a Post graduate Diploma in Human Resource Management from Thames Valley University.

Before she was appointed as Group General Counsel for ADVANZ PHARMA in May 2022, Eve-Anadel Coronado joined Concordia International in 2018 and supported the M&A and BD&L teams. Eve has broad legal experience in international life sciences and held roles at Hikma Pharmaceuticals, Pharmascience and IQVIA (formerly IMS Health) where she worked in the R&D, Scientific Affairs, Business Development, M&A, Global Operations, Supply Chain, Commercial, Marketing and Sales teams. Before venturing into life sciences, Eve also worked for law firms in Paris and Montreal. Eve speaks French, Spanish and English fluently.

Steffen joined ADVANZ PHARMA as CEO in April 2022 and has broad general management experience in international life science businesses. He is a medical doctor by training, has previously held senior roles with STADA, Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain. His industry experience covers Biotech, Pharma, MedTech, Biosimilars, Generics, and OTC. He led businesses such as large European-based multinational Pharmaco, US-based Biotech, and Private Equity portfolio companies and likes to work with strong teams to drive business growth, transformation, and M&A.

Andreas Stickler joined ADVANZ PHARMA from Merck Healthcare, part of Merck KGaA, where he was Chief Financial Officer and also served as Global Head of M&A and Business Development for many years. Before that, he held several finance roles at Hoechst/Aventis and Degussa/Evonik in Treasury, Capital Markets and Risk Management and brings a wealth of Finance, Healthcare and M&A expertise to the team.

Joined in May 2015. Raj has over 25 years of experience in the healthcare industry. He is Head of the Healthcare sector team and he is the responsible advisor for Nordic Capital investments in the sector. Raj holds several non-executive positions including the boards of ERT, ArisGlobal, Alloheim and Royal Brompton and Harefield Hospitals Charity. Prior to joining, Raj’s healthcare experience spans both working as a practitioner, having initially qualified and practiced as a cardiac surgeon at Oxford, through to extensive transactional experience gained as Co-Head of Goldman Sachs healthcare investment banking practice where he advised private equity and corporate clients. Raj holds degrees in medicine and surgery from Imperial College, London as well as being Fellow of the Royal College of Surgeons and an MBA from London Business School.

Rainer joined in June 2019, as a Partner and Co-Head of the DACH region with focus on Nordic Capital’s core sectors Healthcare, Technology & Payments and Financial Services. Rainer joined from Goldman Sachs where he was Managing Director focusing on European healthcare companies. He is of German origin and started his career at McKinsey & Company, working across various industries in the DACH region. Rainer studied business administration at WHU Koblenz and holds a doctorate/PhD from Friedrich-Alexander-Universität Erlangen-Nürnberg.